A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R.K. Kelley,E. Gane,E. Assenat,J. Siebler,P.R. Galle,P. Merle,I.O. Hourmand,A. Cleverly,Y. Zhao,I. Gueorguieva,M. Lahn,S. Faivre,K.A. Benhadji,G. Giannelli
DOI: https://doi.org/10.14309/ctg.0000000000000056
2019-07-01
Clinical and Translational Gastroenterology
Abstract:Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, which was the second most common cause of global cancer mortality in 2012 (<sup><a href="#R1-8">1</a></sup>). In the United States, mortality from liver cancer is rising faster than from any other cancer (<sup><a href="#R2-8">2</a></sup>). HCC is associated with chronic liver diseases such as hepatitis B or C virus infection, nonalcoholic fatty liver disease, alcoholic liver disease, and cirrhosis. HCC is most often diagnosed at a late stage, when surgical treatment is no longer an option and systemic therapy is minimally effective. Sorafenib, a multikinase inhibitor approved in 2007 for liver cancer, is the first-line standard-of-care for patients with advanced Barcelona Clinic Liver Cancer stage C HCC or intermediate Barcelona Clinic Liver Cancer stage B HCC noneligible or after failure of chemoembolization (<sup><a href="#R3-8">3</a></sup>). In randomized studies of advanced HCC patients with Child-Pugh A liver function, sorafenib was associated with improved survival compared to placebo in both a Western population in the SHARP trial (overall survival [OS] 10.7 vs 7.9 months, hazard ratio 0.69) and a predominantly Asian hepatitis B virus-positive population (OS 6.5 vs 4.2 months, hazard ratio 0.68) (<sup><a href="#R4-8">4,5</a></sup>). After progression on sorafenib, regorafenib, cabozantinib, and ramucirumab have improved survival in phase 3 trials (<sup><a href="#R6-8">6–8</a></sup>). Recent studies of PD-1 immune checkpoint inhibitors in HCC have demonstrated prolonged, durable responses, leading to regulatory approval in the United States (<sup><a href="#R9-8">9,10</a></sup>). In the front-line setting for advanced HCC, the multikinase inhibitor, lenvatinib, demonstrated noninferiority to sorafenib in the REFLECT trial (<sup><a href="#R11-8">11</a></sup>), but multiple drugs and combination regimens have failed to improve upon the outcomes of sorafenib monotherapy (<sup><a href="#R12-8">12</a></sup>).
gastroenterology & hepatology